These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 11787013

  • 1. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
    Wootton DM, Popel AS, Alevriadou BR.
    Biotechnol Bioeng; 2002 Feb 15; 77(4):405-19. PubMed ID: 11787013
    [Abstract] [Full Text] [Related]

  • 2. The effect of flow on lysis of plasma clots in a plasma environment.
    Sakharov DV, Rijken DC.
    Thromb Haemost; 2000 Mar 15; 83(3):469-74. PubMed ID: 10744155
    [Abstract] [Full Text] [Related]

  • 3. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV, Barrertt-Bergshoeff M, Hekkenberg RT, Rijken DC.
    Thromb Haemost; 1999 Apr 15; 81(4):605-12. PubMed ID: 10235448
    [Abstract] [Full Text] [Related]

  • 4. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis.
    Wu JH, Siddiqui K, Diamond SL.
    Thromb Haemost; 1994 Jul 15; 72(1):105-12. PubMed ID: 7974357
    [Abstract] [Full Text] [Related]

  • 5. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA, Huang TC, Keyt BA, Alevriadou BR.
    Ann Biomed Eng; 1998 Jul 15; 26(4):712-24. PubMed ID: 9662163
    [Abstract] [Full Text] [Related]

  • 6. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov 15; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 7. Biochemical and biophysical conditions for blood clot lysis.
    Sabovic M, Blinc A.
    Pflugers Arch; 2000 Nov 15; 440(5 Suppl):R134-6. PubMed ID: 11005642
    [Abstract] [Full Text] [Related]

  • 8. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M, Lijnen HR, Keber D, Collen D.
    Thromb Haemost; 1989 Dec 29; 62(4):1083-7. PubMed ID: 2515603
    [Abstract] [Full Text] [Related]

  • 9. Properties of thrombolytic agents in vitro using a perfusion circuit attaining shear stress at physiological levels.
    Nishino N, Scully MF, Rampling MW, Kakkar VV.
    Thromb Haemost; 1990 Dec 28; 64(4):550-5. PubMed ID: 2128138
    [Abstract] [Full Text] [Related]

  • 10. High accumulation of plasminogen and tissue plasminogen activator at the flow surface of mural fibrin in the human arterial system.
    Sasajima T, Takano Y, Hiraishi Y, Goh K, Inaba M, Azuma N, Sasajima Y, Yamazaki K, Yamamoto H.
    J Vasc Surg; 2000 Aug 28; 32(2):374-82. PubMed ID: 10917998
    [Abstract] [Full Text] [Related]

  • 11. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH, Diamond SL.
    J Clin Invest; 1995 Jun 28; 95(6):2483-90. PubMed ID: 7769094
    [Abstract] [Full Text] [Related]

  • 12. Enzyme-mediated proteolysis of fibrous biopolymers: Dissolution front movement in fibrin or collagen under conditions of diffusive or convective transport.
    Anand S, Wu JH, Diamond SL.
    Biotechnol Bioeng; 1995 Oct 20; 48(2):89-107. PubMed ID: 18623465
    [Abstract] [Full Text] [Related]

  • 13. Inner clot diffusion and permeation during fibrinolysis.
    Diamond SL, Anand S.
    Biophys J; 1993 Dec 20; 65(6):2622-43. PubMed ID: 8312497
    [Abstract] [Full Text] [Related]

  • 14. Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins.
    Gombás J, Tanka-Salamon A, Skopál J, Nagy Z, Machovich R, Kolev K.
    Blood Coagul Fibrinolysis; 2008 Jan 20; 19(1):82-8. PubMed ID: 18180621
    [Abstract] [Full Text] [Related]

  • 15. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.
    Jones AJ, Meunier AM.
    Thromb Haemost; 1990 Nov 30; 64(3):455-63. PubMed ID: 2128976
    [Abstract] [Full Text] [Related]

  • 16. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
    Ganguly K, Goel MS, Krasik T, Bdeir K, Diamond SL, Cines DB, Muzykantov VR, Murciano JC.
    J Pharmacol Exp Ther; 2006 Mar 30; 316(3):1130-6. PubMed ID: 16284278
    [Abstract] [Full Text] [Related]

  • 17. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
    Leaker MT, Brooker LA, Mitchell LG, Weitz JI, Superina R, Andrew ME.
    Transplantation; 1995 Jul 27; 60(2):144-7. PubMed ID: 7624956
    [Abstract] [Full Text] [Related]

  • 18. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
    Nielsen VG.
    Blood Coagul Fibrinolysis; 2010 Sep 27; 21(6):584-7. PubMed ID: 20683324
    [Abstract] [Full Text] [Related]

  • 19. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
    Schaefer AV, Leslie BA, Rischke JA, Stafford AR, Fredenburgh JC, Weitz JI.
    Biochemistry; 2006 Apr 04; 45(13):4257-65. PubMed ID: 16566600
    [Abstract] [Full Text] [Related]

  • 20. The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases.
    Zidansek A, Blinc A.
    Thromb Haemost; 1991 May 06; 65(5):553-9. PubMed ID: 1831302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.